Historical Valuation
Skye Bioscience Inc (SKYE) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.31. The fair price of Skye Bioscience Inc (SKYE) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：0.99
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Skye Bioscience Inc (SKYE) has a current Price-to-Book (P/B) ratio of 0.83. Compared to its 3-year average P/B ratio of -2.08 , the current P/B ratio is approximately -139.91% higher. Relative to its 5-year average P/B ratio of 1.96, the current P/B ratio is about -57.66% higher. Skye Bioscience Inc (SKYE) has a Forward Free Cash Flow (FCF) yield of approximately -147.50%. Compared to its 3-year average FCF yield of -43.25%, the current FCF yield is approximately 241.01% lower. Relative to its 5-year average FCF yield of -39.97% , the current FCF yield is about 269.02% lower.
P/B
Median3y
-2.08
Median5y
1.96
FCF Yield
Median3y
-43.25
Median5y
-39.97
Competitors Valuation Multiple
AI Analysis for SKYE
The average P/S ratio for SKYE competitors is 4.33, providing a benchmark for relative valuation. Skye Bioscience Inc Corp (SKYE.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for SKYE
1Y
3Y
5Y
Market capitalization of SKYE increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of SKYE in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is SKYE currently overvalued or undervalued?
Skye Bioscience Inc (SKYE) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.31. The fair price of Skye Bioscience Inc (SKYE) is between to according to relative valuation methord.
What is Skye Bioscience Inc (SKYE) fair value?
SKYE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Skye Bioscience Inc (SKYE) is between to according to relative valuation methord.
How does SKYE's valuation metrics compare to the industry average?
The average P/S ratio for SKYE's competitors is 4.33, providing a benchmark for relative valuation. Skye Bioscience Inc Corp (SKYE) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Skye Bioscience Inc (SKYE) as of Jan 09 2026?
As of Jan 09 2026, Skye Bioscience Inc (SKYE) has a P/B ratio of 0.83. This indicates that the market values SKYE at 0.83 times its book value.
What is the current FCF Yield for Skye Bioscience Inc (SKYE) as of Jan 09 2026?
As of Jan 09 2026, Skye Bioscience Inc (SKYE) has a FCF Yield of -147.50%. This means that for every dollar of Skye Bioscience Inc’s market capitalization, the company generates -147.50 cents in free cash flow.
What is the current Forward P/E ratio for Skye Bioscience Inc (SKYE) as of Jan 09 2026?
As of Jan 09 2026, Skye Bioscience Inc (SKYE) has a Forward P/E ratio of -0.74. This means the market is willing to pay $-0.74 for every dollar of Skye Bioscience Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Skye Bioscience Inc (SKYE) as of Jan 09 2026?
As of Jan 09 2026, Skye Bioscience Inc (SKYE) has a Forward P/S ratio of 0.00. This means the market is valuing SKYE at $0.00 for every dollar of expected revenue over the next 12 months.